UCLA, UT Southwestern join NCCN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

UCLA Jonsson Comprehensive Cancer Center and UT Southwestern Simmons Comprehensive Cancer Center are the newest members of the National Comprehensive Cancer Network.

Experts from both centers will now contribute to NCCN Clinical Practice Guidelines in Oncology.

“We look forward to joining our peer institutions and bringing our focus on cutting-edge research and top-quality cancer care to this association of the nation’s top cancer centers,” Michael Teitell, director of UCLA Jonsson Comprehensive Cancer Center, said in as statement.

“We are excited to be able to join forces with the other leading cancer centers who are part of NCCN,” John Sweetenham, associate director of Clinical Affairs, UT Southwestern Simmons Comprehensive Cancer Center, said in a statement. “Working with the other member institutions, we will ensure that the best possible evidence-based cancer care is available to patients throughout the nation and beyond. Our membership will bring the combined expertise of 30 elite cancer centers to the people of North Texas.”

In 2019, more than 1,500 experts from NCCN member institutions helped create and update NCCN Guidelines. Those guidelines provide the latest evidence- and expert consensus-based recommendations applying to 97% of cancers affecting patients in the United States, and also include prevention, screening, and supportive care topics.

Table of Contents

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For the past four decades, psilocybin research has focused on one area: the treatment of mental health disorders, including depression, anxiety, existential distress associated with serious medical illnesses, post-traumatic stress disorder, and addiction.
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login